Evidence for the Use of Janus Kinase (JAK) Inhibitors in the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Scoping Review.

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe mucocutaneous adverse drug reactions associated with high morbidity and mortality. Current treatment regimens are largely supportive, and evidence for adjunctive systemic…

Preview only. Read the full abstract at the source